The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of exemestane plus everolimus on CTC counts and Ki-67 expression on CTCs in patients with advanced hormone receptor-positive, HER2-negative breast cancer.
Sofia Agelaki
No relevant relationships to disclose
Maria Spiliotaki
No relevant relationships to disclose
Christos Nikolaou
No relevant relationships to disclose
Eleni Politaki
No relevant relationships to disclose
Stella Apostolaki
No relevant relationships to disclose
Athanasios Kotsakis
No relevant relationships to disclose
Dimitrios Mavroudis
No relevant relationships to disclose
Vassilis Georgoulias
Consultant or Advisory Role - Novartis